Skip to main content

Allos Therapeutics, Inc. has submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for the use of pralatrexate for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). The company has requested a priority review of the application. There are currently no agents approved by the FDA for the treatment of patients with PTCL.

Pralatrexate is a novel, targeted antifolate designed to accumulate preferentially in cancer cells. Acting on the folate pathway, pralatrexate interferes with DNA synthesis and triggers cell death.

The NDA for pralatrexate is based on results from the pivotal Phase II trial known as PROPEL (Pralatrexate in patients with Relapsed Or refractory PEripheral T-cell Lymphoma). In this international, multicenter, open-label, single-arm trial, 27% of patients achieved a response to treatment; median duration of response was 9.4 months.

Scroll to Continue

Recommended Articles

Image placeholder title

Relatlimab Anti-LAG-3 Antibody

Is combination immunotherapy with the anti-LAG-3 antibody relatlimab and Opdivo the next advance in melanoma treatment?

Image placeholder title

Blood Cancers and COVID-19 - What You Need to Know

COCID-19 puts individuals with leukemia, lymphoma, myeloma and MPN's at risk - learn how to optimize your care.